Related Experiment Video
Updated: May 12, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention
Karen S Pieper1, Anastasios A Tsiatis, Marie Davidian
1Duke Clinical Research Institute and Department of Medicine, Duke University Medical Center, Durham, NC 27715, USA. karen.pieper@duke.edu
Circulation
|February 11, 2004
Summary
Platelet glycoprotein IIb/IIIa inhibitors are not exclusively for percutaneous coronary intervention. Relying on subgroup analyses for clinical decisions can be misleading; overall trial results are more reliable for practice guidelines.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Platelet glycoprotein IIb/IIIa inhibitors are often restricted to acute coronary syndrome patients undergoing percutaneous coronary intervention.
- Evidence supporting this narrow application, derived from randomized clinical trials, is weak.
- Current practice is influenced by subgroup analyses, which may be inappropriate.
Purpose of the Study:
- To evaluate the validity of subgroup analyses in determining the use of glycoprotein IIb/IIIa inhibitors.
- To challenge the assumption that these inhibitors are only effective during percutaneous coronary intervention.
Main Methods:
- Analysis of data from randomized clinical trials on glycoprotein IIb/IIIa inhibitors.
- Critique of analytical techniques used in subgroup analyses.
- Demonstration of how different analytical approaches yield conflicting results.
Main Results:
- Subgroup analyses across trials have been methodologically flawed.
- Different analytical methods produce contradictory conclusions regarding inhibitor efficacy.
- The assumption of percutaneous coronary intervention-specific benefit is not robustly supported.
Conclusions:
- Clinical practice decisions should prioritize overall trial findings over subgroup analyses.
- Practice guidelines for glycoprotein IIb/IIIa inhibitors should be informed by comprehensive trial data.
- Post-randomization subgroup analyses are unreliable for guiding clinical practice.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...